- Home
- CBNA vs OBIO Comparison
CBNA vs OBIO Comparison
Compare CBNA & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBNA
- OBIO
- Stock Information
- Founded
- CBNA 2006
- OBIO 2017
- Country
- CBNA United States
- OBIO United States
- Employees
- CBNA N/A
- OBIO N/A
- Industry
- CBNA
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- CBNA
- OBIO Health Care
- Exchange
- CBNA NYSE
- OBIO Nasdaq
- Market Cap
- CBNA 159.8M
- OBIO 151.3M
- IPO Year
- CBNA 2024
- OBIO N/A
- Fundamental
- Price
- CBNA $24.48
- OBIO $2.85
- Analyst Decision
- CBNA Buy
- OBIO Strong Buy
- Analyst Count
- CBNA 3
- OBIO 5
- Target Price
- CBNA $29.67
- OBIO $15.00
- AVG Volume (30 Days)
- CBNA 14.0K
- OBIO 69.1K
- Earning Date
- CBNA 05-15-2025
- OBIO 05-12-2025
- Dividend Yield
- CBNA N/A
- OBIO N/A
- EPS Growth
- CBNA 115.79
- OBIO N/A
- EPS
- CBNA 4.17
- OBIO N/A
- Revenue
- CBNA $53,113,000.00
- OBIO $2,638,000.00
- Revenue This Year
- CBNA N/A
- OBIO $27.37
- Revenue Next Year
- CBNA $22.92
- OBIO $42.68
- P/E Ratio
- CBNA $5.87
- OBIO N/A
- Revenue Growth
- CBNA 74.81
- OBIO N/A
- 52 Week Low
- CBNA $20.01
- OBIO $2.49
- 52 Week High
- CBNA $27.56
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- CBNA N/A
- OBIO 36.86
- Support Level
- CBNA N/A
- OBIO $2.75
- Resistance Level
- CBNA N/A
- OBIO $3.26
- Average True Range (ATR)
- CBNA 0.00
- OBIO 0.48
- MACD
- CBNA 0.00
- OBIO -0.01
- Stochastic Oscillator
- CBNA 0.00
- OBIO 16.82
About CBNA CHAIN BRIDGE BANCORP INC
Chain Bridge Bancorp Inc is engaged in banking industry. It offers commercial and personal banking services, including deposits, treasury management, payments, loans, commercial lending, residential mortgage financing, consumer loans, trusts and estate administration, wealth management, and asset custody.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.